Quantcast
Last updated on April 23, 2014 at 13:54 EDT

Latest Inhaler Stories

2011-09-26 07:00:00

SAN DIEGO, Sept. 26, 2011 /PRNewswire/ -- Elevation Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of new aerosol therapies for patients with respiratory diseases, announced today that it presented positive results from a Phase 2a study of EP-101 in patients with moderate to severe chronic obstructive pulmonary disease (COPD), a large and growing disease characterized by significant unmet clinical needs, at the annual meeting of the European Respiratory...

FDA To Phase Out Some Primatene Asthma Inhalers
2011-09-23 09:29:23

  An over-the-counter asthma inhaler is to be banned beginning next year because federal health officials said it produces carbon gas that is harmful to the environment, Reuters reports. The inhaler in question is currently the only over-the-counter inhaler on the market, which when banned, will leave asthma patients with only prescription-based choices. The Food and Drug Administration said on Thursday that chlorofluorocarbons (CFCs) in the metered-dose inhalers that contain...

2011-09-22 08:03:00

Users of Primatene Mist will need a prescription product to treat their asthma SILVER SPRING, Md., Sept. 22, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration says users of epinephrine inhalers containing chlorofluorocarbons (CFCs) should plan now to get a prescription for a replacement product because these inhalers will not be made or sold after Dec. 31, 2011. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO) Epinephrine inhalers, marketed by Armstrong...

2011-09-06 14:53:00

REDWOOD CITY, Calif., Sept. 6, 2011 /PRNewswire/ -- Pearl Therapeutics was named by FierceBiotech today as one of 2011's Fierce 15, designating it as one of the most promising private biotechnology companies in the industry. This is FierceBiotech's ninth annual Fierce 15 selection. "Pearl's veteran team has done a super job of raising the funds and doing clinical research to advance PT003 - an inhaled LAMA/LABA combination therapy - toward the market," says Ryan McBride, the executive...

2011-08-30 14:00:00

REDWOOD CITY, Calif., Aug. 30, 2011 /PRNewswire/ -- Pearl Therapeutics Inc. today announced positive results from a randomized, double-blind, Phase 2b, dose-ranging study of its formoterol fumarate metered dose inhaler (FF MDI; PT005), a long-acting beta-2 agonist (LABA) compared to placebo and Foradil® Aerolizer® in patients with moderate-to-severe COPD. All doses of FF MDI tested produced highly statistically significant improvements in lung function...

2011-07-28 10:00:00

LOS ANGELES, July 28, 2011 /PRNewswire/ -- UBM Canon has announced that it will produce the Pharmapack North America conference and exhibition May 22-23, 2012 in Philadelphia's PA Convention Center. The technology-focused conference and exhibition, which focuses upon innovation in packaging technology and drug delivery systems to enhance health product safety, is the counterpart of the company's highly successful show in Paris, France. (Logo:...

2011-07-26 08:00:00

CANTON, Mass., July 26, 2011 /PRNewswire/ -- Armstrong Pharmaceuticals, Inc. announced the following news today concerning the future availability of Primatene® Mist: On December 31, 2011, the FDA ban on the sale of Primatene® Mist containing CFCs (chlorofluorocarbons) as a propellant will become effective. Primatene® Mist has proven to be a safe and effective treatment for asthma symptoms for over 40 years. The ban on the sale of...

2011-06-17 06:37:04

(Ivanhoe Newswire) -- People who use a mist inhaler to deliver a drug widely prescribed in more than 55 countries to treat chronic obstructive pulmonary disease (COPD) may be 52 percent more likely to die, according to this study. The findings raise concerns not only about the mist inhaler- a device that delivers a soluble form of the medication tiotropium- but also about the drug itself. The mist inhaler isn't approved in the U.S., but the drug in its powdered form is commonly used to treat...

2011-06-16 08:00:00

REDWOOD CITY, Calif., June 16, 2011 /PRNewswire/ -- Pearl Therapeutics Inc. today announced the advancement of its dual combination product candidate, PT003 and its individual components, PT001 and PT005 into a series of planned Phase 2 studies in patients with moderate-to-severe COPD. PT003 (GFF MDI) is an investigational inhaled combination bronchodilator product comprising glycopyrrolate (GP), a long-acting muscarinic antagonist (LAMA), and formoterol (FF), a well-known, established,...

744403bb4a8fbf538c22ac91a65dafe9
2011-06-16 05:35:00

According to new study, Respimat, a mist inhaler that delivers a widely-prescribed respiratory drug, increases the risk of dying by half. The British and U.S. researchers looked at five trials involving Respimat, which can be alternatively taken in powder form. The drug Respimat uses tiotropium bromide, which relaxes muscles in the airways.  It is designed to ease symptoms of chronic obstructive respiratory disease (COPD), the world's fourth leading cause of death. The study was an...